Sareum

Sareum is a clinical-stage biotechnology company developing small molecule kinase inhibitors for the treatment of autoimmune diseases and cancer.

The company's pipeline centres on dual TYK2/JAK1 inhibition, with programmes targeting psoriasis, rheumatoid arthritis, lupus, inflammatory bowel disease and cancer immunotherapy, alongside a Chk1 inhibitor programme in oncology.

Programmes are advanced to early clinical stage before out-licensing to pharmaceutical and biotechnology partners.

Sareum is listed on the AIM market of the London Stock Exchange.